ENSG00000100393 |
EP300 |
colorectal adenocarcinoma |
missense_variant |
6.147% (97/1578) |
6 entries |
ENSG00000100393 |
EP300 |
esophageal squamous cell carcinoma |
missense_variant |
9.544% (90/943) |
6 entries |
ENSG00000100393 |
EP300 |
urothelial carcinoma |
stop_gained |
13.95% (12/86) |
1 entry |
ENSG00000100393 |
EP300 |
urothelial carcinoma |
frameshift_variant |
13.95% (12/86) |
1 entry |
ENSG00000100393 |
EP300 |
myelodysplastic syndrome |
stop_gained |
23.5% (47/200) |
1 entry |
ENSG00000100393 |
EP300 |
colon adenocarcinoma |
missense_variant |
5.957% (80/1343) |
8 entries |
ENSG00000100393 |
EP300 |
cecum adenocarcinoma |
frameshift_variant |
8.889% (24/270) |
1 entry |
ENSG00000100393 |
EP300 |
esophageal squamous cell carcinoma |
frameshift_variant |
9.544% (90/943) |
3 entries |
ENSG00000100393 |
EP300 |
colorectal adenocarcinoma |
frameshift_variant |
6.147% (97/1578) |
5 entries |
ENSG00000100393 |
EP300 |
bladder carcinoma |
missense_variant |
11.87% (68/573) |
1 entry |
ENSG00000100393 |
EP300 |
bladder transitional cell carcinoma |
conservative_inframe_deletion |
12.35% (73/591) |
1 entry |
ENSG00000100393 |
EP300 |
myelodysplastic syndrome |
missense_variant |
23.5% (47/200) |
3 entries |
ENSG00000100393 |
EP300 |
colorectal adenocarcinoma |
stop_gained |
6.147% (97/1578) |
5 entries |
ENSG00000100393 |
EP300 |
colorectal adenocarcinoma |
sequence_alteration |
6.147% (97/1578) |
3 entries |
ENSG00000100393 |
EP300 |
lung carcinoma |
sequence_alteration |
18.33% (22/120) |
1 entry |
ENSG00000100393 |
EP300 |
bladder transitional cell carcinoma |
frameshift_variant |
12.35% (73/591) |
3 entries |
ENSG00000100393 |
EP300 |
bladder carcinoma |
stop_gained |
11.87% (68/573) |
1 entry |
ENSG00000100393 |
EP300 |
esophageal squamous cell carcinoma |
stop_gained |
9.544% (90/943) |
4 entries |
ENSG00000100393 |
EP300 |
melanoma |
missense_variant |
13.1% (19/145) |
3 entries |
ENSG00000100393 |
EP300 |
esophageal squamous cell carcinoma |
sequence_alteration |
9.544% (90/943) |
4 entries |
ENSG00000100393 |
EP300 |
esophageal squamous cell carcinoma |
conservative_inframe_deletion |
9.544% (90/943) |
2 entries |
ENSG00000100393 |
EP300 |
bladder carcinoma |
conservative_inframe_deletion |
11.87% (68/573) |
1 entry |
ENSG00000100393 |
EP300 |
lymphoid neoplasm |
stop_gained |
13.71% (27/197) |
1 entry |
ENSG00000100393 |
EP300 |
bladder transitional cell carcinoma |
sequence_alteration |
12.35% (73/591) |
4 entries |
ENSG00000100393 |
EP300 |
bladder carcinoma |
sequence_alteration |
11.87% (68/573) |
2 entries |
ENSG00000100393 |
EP300 |
colon adenocarcinoma |
sequence_alteration |
5.957% (80/1343) |
2 entries |
ENSG00000100393 |
EP300 |
myelodysplastic syndrome |
frameshift_variant |
23.5% (47/200) |
1 entry |
ENSG00000100393 |
EP300 |
colon adenocarcinoma |
frameshift_variant |
5.957% (80/1343) |
6 entries |
ENSG00000100393 |
EP300 |
colon adenocarcinoma |
stop_gained |
5.957% (80/1343) |
6 entries |
ENSG00000100393 |
EP300 |
myelodysplastic syndrome |
conservative_inframe_deletion |
23.5% (47/200) |
1 entry |
ENSG00000100393 |
EP300 |
bladder carcinoma |
frameshift_variant |
11.87% (68/573) |
2 entries |
ENSG00000100393 |
EP300 |
bladder transitional cell carcinoma |
missense_variant |
12.35% (73/591) |
5 entries |
ENSG00000100393 |
EP300 |
cecum adenocarcinoma |
stop_gained |
8.889% (24/270) |
1 entry |
ENSG00000100393 |
EP300 |
bladder transitional cell carcinoma |
stop_gained |
12.35% (73/591) |
6 entries |
ENSG00000100393 |
EP300 |
cecum adenocarcinoma |
sequence_alteration |
8.889% (24/270) |
1 entry |
ENSG00000100393 |
EP300 |
urothelial carcinoma |
missense_variant |
13.95% (12/86) |
1 entry |
ENSG00000100393 |
EP300 |
cecum adenocarcinoma |
missense_variant |
8.889% (24/270) |
3 entries |
ENSG00000100393 |
EP300 |
HER2 Positive Breast Carcinoma |
missense_variant |
4.787% (9/188) |
4 entries |
ENSG00000100393 |
EP300 |
urothelial carcinoma |
sequence_alteration |
13.95% (12/86) |
1 entry |
ENSG00000100393 |
EP300 |
kidney Wilms tumor |
conservative_inframe_deletion |
0.6173% (6/972) |
1 entry |
ENSG00000100393 |
EP300 |
T-cell acute lymphoblastic leukemia |
missense_variant |
3.033% (30/989) |
3 entries |
ENSG00000100393 |
EP300 |
T-cell acute lymphoblastic leukemia |
conservative_inframe_deletion |
3.033% (30/989) |
2 entries |
ENSG00000100393 |
EP300 |
pancreatic ductal adenocarcinoma |
missense_variant |
1.966% (34/1729) |
4 entries |
ENSG00000100393 |
EP300 |
Anal Squamous Cell Carcinoma |
sequence_alteration |
12.05% (10/83) |
2 entries |
ENSG00000100393 |
EP300 |
papillary renal cell carcinoma |
missense_variant |
0.5155% (2/388) |
1 entry |
ENSG00000100393 |
EP300 |
gastric adenocarcinoma |
frameshift_variant |
2.839% (27/951) |
1 entry |
ENSG00000100393 |
EP300 |
glioma |
stop_gained |
0.487% (3/616) |
2 entries |
ENSG00000100393 |
EP300 |
marginal zone B-cell lymphoma |
missense_variant |
9.756% (4/41) |
2 entries |
ENSG00000100393 |
EP300 |
bile duct adenocarcinoma |
missense_variant |
0.8945% (5/559) |
1 entry |
ENSG00000100393 |
EP300 |
breast carcinoma |
sequence_alteration |
1.918% (31/1616) |
1 entry |
ENSG00000100393 |
EP300 |
Ampulla of Vater Carcinoma |
missense_variant |
2.353% (2/85) |
1 entry |
ENSG00000100393 |
EP300 |
T-cell acute lymphoblastic leukemia |
frameshift_variant |
3.033% (30/989) |
3 entries |
ENSG00000100393 |
EP300 |
gastric adenocarcinoma |
missense_variant |
2.839% (27/951) |
3 entries |
ENSG00000100393 |
EP300 |
prostate adenocarcinoma |
missense_variant |
3.03% (67/2211) |
3 entries |
ENSG00000100393 |
EP300 |
Merkel cell skin cancer |
missense_variant |
5.263% (5/95) |
2 entries |
ENSG00000100393 |
EP300 |
renal cell carcinoma |
frameshift_variant |
5.882% (4/68) |
1 entry |
ENSG00000100393 |
EP300 |
head and neck squamous cell carcinoma |
sequence_alteration |
2.937% (22/749) |
1 entry |
ENSG00000100393 |
EP300 |
lung adenocarcinoma |
frameshift_variant |
2.128% (57/2679) |
2 entries |
ENSG00000100393 |
EP300 |
breast carcinoma |
frameshift_variant |
1.918% (31/1616) |
1 entry |
ENSG00000100393 |
EP300 |
hepatocellular carcinoma |
missense_variant |
1.52% (15/987) |
2 entries |
ENSG00000100393 |
EP300 |
basal cell carcinoma |
missense_variant |
10.29% (7/68) |
1 entry |
ENSG00000100393 |
EP300 |
female breast carcinoma |
missense_variant |
2.244% (9/401) |
1 entry |
ENSG00000100393 |
EP300 |
melanoma |
sequence_alteration |
13.1% (19/145) |
1 entry |
ENSG00000100393 |
EP300 |
brain glioblastoma |
sequence_alteration |
0.898% (11/1225) |
1 entry |
ENSG00000100393 |
EP300 |
Gallbladder Adenocarcinoma |
sequence_alteration |
1.571% (3/191) |
1 entry |
ENSG00000100393 |
EP300 |
skin melanoma |
stop_gained |
3.442% (40/1162) |
1 entry |
ENSG00000100393 |
EP300 |
Cervical Small Cell Carcinoma |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000100393 |
EP300 |
oral squamous cell carcinoma |
missense_variant |
4.114% (13/316) |
9 entries |
ENSG00000100393 |
EP300 |
adenosquamous lung carcinoma |
missense_variant |
13.64% (3/22) |
2 entries |
ENSG00000100393 |
EP300 |
nasopharyngeal squamous cell carcinoma |
stop_gained |
2.922% (9/308) |
1 entry |
ENSG00000100393 |
EP300 |
chronic myelomonocytic leukemia |
missense_variant |
6.818% (6/88) |
1 entry |
ENSG00000100393 |
EP300 |
acute myeloid leukemia |
frameshift_variant |
1.596% (42/2631) |
3 entries |
ENSG00000100393 |
EP300 |
Anal Squamous Cell Carcinoma |
missense_variant |
12.05% (10/83) |
2 entries |
ENSG00000100393 |
EP300 |
rectal adenocarcinoma |
conservative_inframe_deletion |
2.545% (14/550) |
1 entry |
ENSG00000100393 |
EP300 |
cervical squamous cell carcinoma |
missense_variant |
6.154% (20/325) |
1 entry |
ENSG00000100393 |
EP300 |
dedifferentiated liposarcoma |
missense_variant |
4.444% (2/45) |
1 entry |
ENSG00000100393 |
EP300 |
esophageal adenocarcinoma |
missense_variant |
4.015% (22/548) |
2 entries |
ENSG00000100393 |
EP300 |
pharyngeal squamous cell carcinoma |
stop_gained |
6.993% (10/143) |
1 entry |
ENSG00000100393 |
EP300 |
lung adenocarcinoma |
sequence_alteration |
2.128% (57/2679) |
1 entry |
ENSG00000100393 |
EP300 |
rectal adenocarcinoma |
missense_variant |
2.545% (14/550) |
3 entries |
ENSG00000100393 |
EP300 |
gastric intestinal type adenocarcinoma |
missense_variant |
5.102% (5/98) |
2 entries |
ENSG00000100393 |
EP300 |
small cell lung carcinoma |
missense_variant |
6.843% (31/453) |
4 entries |
ENSG00000100393 |
EP300 |
pleomorphic liposarcoma |
frameshift_variant |
33.33% (3/9) |
2 entries |
ENSG00000100393 |
EP300 |
diffuse large B-cell lymphoma |
missense_variant |
5.164% (30/581) |
7 entries |
ENSG00000100393 |
EP300 |
breast carcinoma |
missense_variant |
1.918% (31/1616) |
4 entries |
ENSG00000100393 |
EP300 |
T-cell acute lymphoblastic leukemia |
amino_acid_insertion |
3.033% (30/989) |
2 entries |
ENSG00000100393 |
EP300 |
endometrial carcinoma |
missense_variant |
7.143% (5/70) |
2 entries |
ENSG00000100393 |
EP300 |
acute myeloid leukemia |
missense_variant |
1.596% (42/2631) |
2 entries |
ENSG00000100393 |
EP300 |
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
5.538% (36/650) |
1 entry |
ENSG00000100393 |
EP300 |
hemangioblastoma |
sequence_alteration |
11.43% (4/35) |
1 entry |
ENSG00000100393 |
EP300 |
salivary gland adenoid cystic carcinoma |
frameshift_variant |
4.688% (3/64) |
2 entries |
ENSG00000100393 |
EP300 |
breast ductal adenocarcinoma |
sequence_alteration |
3.002% (48/1599) |
1 entry |
ENSG00000100393 |
EP300 |
acute myeloid leukemia |
sequence_alteration |
1.596% (42/2631) |
1 entry |
ENSG00000100393 |
EP300 |
Pleural Mesothelioma |
missense_variant |
1.399% (2/143) |
2 entries |
ENSG00000100393 |
EP300 |
undifferentiated pleomorphic sarcoma |
missense_variant |
3.226% (2/62) |
1 entry |
ENSG00000100393 |
EP300 |
osteosarcoma |
missense_variant |
1.316% (2/152) |
1 entry |
ENSG00000100393 |
EP300 |
acute lymphoblastic leukemia |
missense_variant |
0.9547% (4/419) |
1 entry |
ENSG00000100393 |
EP300 |
ovarian carcinoma |
frameshift_variant |
1.98% (4/202) |
2 entries |
ENSG00000100393 |
EP300 |
anaplastic astrocytoma |
missense_variant |
2.158% (3/139) |
2 entries |
ENSG00000100393 |
EP300 |
mucosal melanoma |
missense_variant |
2.857% (2/70) |
2 entries |
ENSG00000100393 |
EP300 |
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
5.538% (36/650) |
2 entries |
ENSG00000100393 |
EP300 |
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
1.116% (5/448) |
2 entries |
ENSG00000100393 |
EP300 |
melanoma |
conservative_inframe_deletion |
13.1% (19/145) |
1 entry |
ENSG00000100393 |
EP300 |
prostate adenocarcinoma |
sequence_alteration |
3.03% (67/2211) |
1 entry |
ENSG00000100393 |
EP300 |
papillary thyroid carcinoma |
missense_variant |
1.217% (6/493) |
1 entry |
ENSG00000100393 |
EP300 |
prostate carcinoma |
sequence_alteration |
2.474% (12/485) |
1 entry |
ENSG00000100393 |
EP300 |
gastric adenocarcinoma |
sequence_alteration |
2.839% (27/951) |
1 entry |
ENSG00000100393 |
EP300 |
pancreatic neuroendocrine tumor |
missense_variant |
2.119% (5/236) |
1 entry |
ENSG00000100393 |
EP300 |
central nervous system primitive neuroectodermal neoplasm |
sequence_alteration |
1.116% (5/448) |
1 entry |
ENSG00000100393 |
EP300 |
neoplasm of mature B-cells |
missense_variant |
10.19% (11/108) |
4 entries |
ENSG00000100393 |
EP300 |
diffuse large B-cell lymphoma |
frameshift_variant |
5.164% (30/581) |
1 entry |
ENSG00000100393 |
EP300 |
Splenic Diffuse Large B-Cell Lymphoma |
missense_variant |
50.0% (2/4) |
2 entries |
ENSG00000100393 |
EP300 |
Gastrointestinal stromal tumor |
missense_variant |
1.316% (2/152) |
1 entry |
ENSG00000100393 |
EP300 |
skin melanoma |
missense_variant |
3.442% (40/1162) |
5 entries |
ENSG00000100393 |
EP300 |
clear cell renal carcinoma |
missense_variant |
0.805% (13/1615) |
2 entries |
ENSG00000100393 |
EP300 |
acute myeloid leukemia |
stop_gained |
1.596% (42/2631) |
2 entries |
ENSG00000100393 |
EP300 |
neoplasm of mature B-cells |
sequence_alteration |
10.19% (11/108) |
1 entry |
ENSG00000100393 |
EP300 |
esophageal squamous cell carcinoma |
stop_lost |
9.544% (90/943) |
1 entry |
ENSG00000100393 |
EP300 |
head and neck squamous cell carcinoma |
stop_gained |
2.937% (22/749) |
2 entries |
ENSG00000100393 |
EP300 |
pharyngeal squamous cell carcinoma |
missense_variant |
6.993% (10/143) |
3 entries |
ENSG00000100393 |
EP300 |
Dysplasia in Ulcerative Colitis |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000100393 |
EP300 |
nasopharyngeal squamous cell carcinoma |
missense_variant |
2.922% (9/308) |
3 entries |
ENSG00000100393 |
EP300 |
T-cell acute lymphoblastic leukemia |
sequence_alteration |
3.033% (30/989) |
3 entries |
ENSG00000100393 |
EP300 |
diffuse large B-cell lymphoma |
stop_gained |
5.164% (30/581) |
2 entries |
ENSG00000100393 |
EP300 |
prostate adenocarcinoma |
stop_gained |
3.03% (67/2211) |
1 entry |
ENSG00000100393 |
EP300 |
head and neck squamous cell carcinoma |
missense_variant |
2.937% (22/749) |
3 entries |
ENSG00000100393 |
EP300 |
squamous cell lung carcinoma |
missense_variant |
3.176% (33/1039) |
6 entries |
ENSG00000100393 |
EP300 |
Breast Carcinoma by Gene Expression Profile |
missense_variant |
4.167% (4/96) |
2 entries |
ENSG00000100393 |
EP300 |
lung adenocarcinoma |
missense_variant |
2.128% (57/2679) |
9 entries |
ENSG00000100393 |
EP300 |
chronic lymphocytic leukemia |
missense_variant |
1.483% (14/944) |
3 entries |
ENSG00000100393 |
EP300 |
T-cell acute lymphoblastic leukemia |
stop_gained |
3.033% (30/989) |
3 entries |
ENSG00000100393 |
EP300 |
breast ductal adenocarcinoma |
missense_variant |
3.002% (48/1599) |
2 entries |
ENSG00000100393 |
EP300 |
non-small cell lung carcinoma |
missense_variant |
2.609% (3/115) |
1 entry |
ENSG00000100393 |
EP300 |
ovarian serous adenocarcinoma |
missense_variant |
0.5931% (5/843) |
1 entry |
ENSG00000100393 |
EP300 |
anaplastic oligodendroglioma |
missense_variant |
3.297% (3/91) |
1 entry |
ENSG00000100393 |
EP300 |
small cell lung carcinoma |
sequence_alteration |
6.843% (31/453) |
2 entries |
ENSG00000100393 |
EP300 |
breast carcinoma |
stop_gained |
1.918% (31/1616) |
1 entry |
ENSG00000100393 |
EP300 |
brain glioblastoma |
missense_variant |
0.898% (11/1225) |
2 entries |
ENSG00000100393 |
EP300 |
neoplasm of mature B-cells |
conservative_inframe_deletion |
10.19% (11/108) |
2 entries |
ENSG00000100393 |
EP300 |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
5.538% (36/650) |
2 entries |
ENSG00000100393 |
EP300 |
diffuse large B-cell lymphoma |
sequence_alteration |
5.164% (30/581) |
2 entries |
ENSG00000100393 |
EP300 |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
stop_gained |
1.901% (5/263) |
2 entries |
ENSG00000100393 |
EP300 |
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
6.25% (4/64) |
3 entries |
ENSG00000100393 |
EP300 |
prostate carcinoma |
missense_variant |
2.474% (12/485) |
4 entries |
ENSG00000100393 |
EP300 |
breast ductal adenocarcinoma |
stop_gained |
3.002% (48/1599) |
1 entry |
ENSG00000100393 |
EP300 |
lung adenocarcinoma |
stop_gained |
2.128% (57/2679) |
4 entries |
ENSG00000100393 |
EP300 |
polycythemia vera |
frameshift_variant |
0.7634% (1/131) |
1 entry |
ENSG00000100393 |
EP300 |
metaplastic breast carcinoma |
missense_variant |
3.333% (2/60) |
1 entry |
ENSG00000100393 |
EP300 |
basal cell carcinoma |
stop_gained |
10.29% (7/68) |
1 entry |
ENSG00000100393 |
EP300 |
Pancreatic Acinar Cell Carcinoma |
missense_variant |
2.941% (1/34) |
1 entry |
ENSG00000100393 |
EP300 |
anaplastic astrocytoma |
stop_gained |
2.158% (3/139) |
1 entry |
ENSG00000100393 |
EP300 |
Parotid Gland Acinic Cell Carcinoma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000100393 |
EP300 |
acute lymphoblastic leukemia |
frameshift_variant |
0.9547% (4/419) |
1 entry |
ENSG00000100393 |
EP300 |
ependymoma |
conservative_inframe_deletion |
1.852% (1/54) |
1 entry |
ENSG00000100393 |
EP300 |
colon carcinoma |
frameshift_variant |
25.0% (2/8) |
1 entry |
ENSG00000100393 |
EP300 |
leiomyoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000100393 |
EP300 |
adrenal cortex carcinoma |
sequence_alteration |
0.9174% (2/218) |
1 entry |
ENSG00000100393 |
EP300 |
diffuse large B-cell lymphoma |
conservative_inframe_deletion |
5.164% (30/581) |
1 entry |
ENSG00000100393 |
EP300 |
lung carcinoid tumor |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000100393 |
EP300 |
esophageal adenocarcinoma |
stop_gained |
4.015% (22/548) |
1 entry |
ENSG00000100393 |
EP300 |
Central Nervous System Lymphoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000100393 |
EP300 |
skin melanoma |
frameshift_variant |
3.442% (40/1162) |
1 entry |
ENSG00000100393 |
EP300 |
ulcerative colitis |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000100393 |
EP300 |
desmoplastic small round cell tumor |
stop_gained |
4.545% (1/22) |
1 entry |
ENSG00000100393 |
EP300 |
pharyngeal squamous cell carcinoma |
frameshift_variant |
6.993% (10/143) |
1 entry |
ENSG00000100393 |
EP300 |
salivary gland carcinoma |
missense_variant |
3.03% (1/33) |
1 entry |
ENSG00000100393 |
EP300 |
Malignant Germ Cell Tumor |
missense_variant |
0.5525% (1/181) |
1 entry |
ENSG00000100393 |
EP300 |
gastric intestinal type adenocarcinoma |
conservative_inframe_deletion |
5.102% (5/98) |
1 entry |
ENSG00000100393 |
EP300 |
skin carcinoma |
missense_variant |
5.769% (6/104) |
1 entry |
ENSG00000100393 |
EP300 |
squamous cell lung carcinoma |
stop_gained |
3.176% (33/1039) |
1 entry |
ENSG00000100393 |
EP300 |
renal cell carcinoma |
missense_variant |
5.882% (4/68) |
1 entry |
ENSG00000100393 |
EP300 |
laryngeal squamous cell carcinoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000100393 |
EP300 |
endometrium adenocarcinoma |
frameshift_variant |
2.941% (1/34) |
1 entry |
ENSG00000100393 |
EP300 |
Vulvar Squamous Cell Carcinoma |
stop_gained |
5.263% (1/19) |
1 entry |
ENSG00000100393 |
EP300 |
gastric intestinal type adenocarcinoma |
sequence_alteration |
5.102% (5/98) |
1 entry |
ENSG00000100393 |
EP300 |
head and neck squamous cell carcinoma |
frameshift_variant |
2.937% (22/749) |
1 entry |
ENSG00000100393 |
EP300 |
nasopharyngeal squamous cell carcinoma |
frameshift_variant |
2.922% (9/308) |
1 entry |
ENSG00000100393 |
EP300 |
lobular breast carcinoma |
missense_variant |
0.4219% (1/237) |
1 entry |
ENSG00000100393 |
EP300 |
glioma |
missense_variant |
0.487% (3/616) |
1 entry |
ENSG00000100393 |
EP300 |
ovarian carcinoma |
stop_gained |
1.98% (4/202) |
1 entry |
ENSG00000100393 |
EP300 |
brain glioblastoma |
frameshift_variant |
0.898% (11/1225) |
1 entry |
ENSG00000100393 |
EP300 |
ovarian serous adenocarcinoma |
stop_gained |
0.5931% (5/843) |
1 entry |
ENSG00000100393 |
EP300 |
ovarian adenocarcinoma |
missense_variant |
10.0% (1/10) |
1 entry |
ENSG00000100393 |
EP300 |
angioimmunoblastic T-cell lymphoma |
conservative_inframe_deletion |
3.738% (4/107) |
1 entry |
ENSG00000100393 |
EP300 |
oral squamous cell carcinoma |
stop_gained |
4.114% (13/316) |
1 entry |
ENSG00000100393 |
EP300 |
Uterine Carcinosarcoma |
missense_variant |
1.351% (2/148) |
1 entry |
ENSG00000100393 |
EP300 |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
frameshift_variant |
1.901% (5/263) |
1 entry |
ENSG00000100393 |
EP300 |
kidney Wilms tumor |
frameshift_variant |
0.6173% (6/972) |
1 entry |
ENSG00000100393 |
EP300 |
small intestinal adenocarcinoma |
frameshift_variant |
9.524% (2/21) |
1 entry |
ENSG00000100393 |
EP300 |
Cervical Adenosquamous Carcinoma |
frameshift_variant |
20.0% (1/5) |
1 entry |
ENSG00000100393 |
EP300 |
bronchoalveolar adenocarcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000100393 |
EP300 |
Parotid Gland Adenoid Cystic Carcinoma |
stop_gained |
7.692% (1/13) |
1 entry |
ENSG00000100393 |
EP300 |
marginal zone B-cell lymphoma |
conservative_inframe_deletion |
9.756% (4/41) |
1 entry |
ENSG00000100393 |
EP300 |
Parathyroid Gland Carcinoma |
stop_gained |
2.857% (1/35) |
1 entry |
ENSG00000100393 |
EP300 |
angioimmunoblastic T-cell lymphoma |
missense_variant |
3.738% (4/107) |
1 entry |
ENSG00000100393 |
EP300 |
Pleural Epithelioid Mesothelioma |
missense_variant |
0.9756% (2/205) |
1 entry |
ENSG00000100393 |
EP300 |
salivary gland squamous cell carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000100393 |
EP300 |
bile duct adenocarcinoma |
stop_gained |
0.8945% (5/559) |
1 entry |
ENSG00000100393 |
EP300 |
vulvar intraepithelial neoplasia |
missense_variant |
9.091% (1/11) |
1 entry |
ENSG00000100393 |
EP300 |
angioimmunoblastic T-cell lymphoma |
stop_gained |
3.738% (4/107) |
1 entry |
ENSG00000100393 |
EP300 |
gastric intestinal type adenocarcinoma |
frameshift_variant |
5.102% (5/98) |
1 entry |
ENSG00000100393 |
EP300 |
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
2.922% (9/308) |
1 entry |
ENSG00000100393 |
EP300 |
Conjunctival Melanoma |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000100393 |
EP300 |
large cell lung carcinoma |
sequence_alteration |
4.167% (1/24) |
1 entry |
ENSG00000100393 |
EP300 |
meningioma (disease) |
frameshift_variant |
1.37% (1/73) |
1 entry |
ENSG00000100393 |
EP300 |
Merkel cell skin cancer |
sequence_alteration |
5.263% (5/95) |
1 entry |
ENSG00000100393 |
EP300 |
neoplasm |
missense_variant |
3.333% (1/30) |
1 entry |
ENSG00000100393 |
EP300 |
breast ductal adenocarcinoma |
frameshift_variant |
3.002% (48/1599) |
1 entry |
ENSG00000100393 |
EP300 |
Anal Squamous Cell Carcinoma |
stop_gained |
12.05% (10/83) |
1 entry |
ENSG00000100393 |
EP300 |
angioimmunoblastic T-cell lymphoma |
sequence_alteration |
3.738% (4/107) |
1 entry |
ENSG00000100393 |
EP300 |
bile duct adenocarcinoma |
frameshift_variant |
0.8945% (5/559) |
1 entry |
ENSG00000100393 |
EP300 |
chronic myelomonocytic leukemia |
conservative_inframe_deletion |
6.818% (6/88) |
1 entry |
ENSG00000100393 |
EP300 |
testicular seminoma |
missense_variant |
2.564% (2/78) |
1 entry |
ENSG00000100393 |
EP300 |
Bladder Squamous Cell Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000100393 |
EP300 |
small cell lung carcinoma |
frameshift_variant |
6.843% (31/453) |
1 entry |
ENSG00000100393 |
EP300 |
astrocytoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000100393 |
EP300 |
rectal adenocarcinoma |
sequence_alteration |
2.545% (14/550) |
1 entry |
ENSG00000100393 |
EP300 |
pleomorphic liposarcoma |
missense_variant |
33.33% (3/9) |
1 entry |
ENSG00000100393 |
EP300 |
small intestinal adenocarcinoma |
missense_variant |
9.524% (2/21) |
1 entry |
ENSG00000100393 |
EP300 |
Thymic Squamous Cell Carcinoma |
sequence_alteration |
7.407% (2/27) |
1 entry |
ENSG00000100393 |
EP300 |
hemangioblastoma |
missense_variant |
11.43% (4/35) |
1 entry |
ENSG00000100393 |
EP300 |
esophageal adenocarcinoma |
frameshift_variant |
4.015% (22/548) |
1 entry |
ENSG00000100393 |
EP300 |
salivary gland adenoid cystic carcinoma |
sequence_alteration |
4.688% (3/64) |
1 entry |
ENSG00000100393 |
EP300 |
head and neck squamous cell carcinoma |
conservative_inframe_deletion |
2.937% (22/749) |
1 entry |
ENSG00000100393 |
EP300 |
Duodenal Adenocarcinoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000100393 |
EP300 |
testicular seminoma |
stop_gained |
2.564% (2/78) |
1 entry |
ENSG00000100393 |
EP300 |
colon carcinoma |
stop_gained |
25.0% (2/8) |
1 entry |
ENSG00000100393 |
EP300 |
papillary thyroid carcinoma |
stop_gained |
1.217% (6/493) |
1 entry |
ENSG00000100393 |
EP300 |
primary peritoneal carcinoma (disease) |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000100393 |
EP300 |
prostate adenocarcinoma |
conservative_inframe_deletion |
3.03% (67/2211) |
1 entry |
ENSG00000100393 |
EP300 |
bile duct adenocarcinoma |
conservative_inframe_deletion |
0.8945% (5/559) |
1 entry |
ENSG00000100393 |
EP300 |
adrenal cortex carcinoma |
missense_variant |
0.9174% (2/218) |
1 entry |
ENSG00000100393 |
EP300 |
cervical carcinoma |
frameshift_variant |
8.696% (2/23) |
1 entry |
ENSG00000100393 |
EP300 |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
sequence_alteration |
1.901% (5/263) |
1 entry |
ENSG00000100393 |
EP300 |
B-cell acute lymphoblastic leukemia |
missense_variant |
0.6329% (1/158) |
1 entry |
ENSG00000100393 |
EP300 |
Ocular Sebaceous Carcinoma |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000100393 |
EP300 |
Burkitts lymphoma |
stop_gained |
1.235% (1/81) |
1 entry |
ENSG00000100393 |
EP300 |
anaplastic oligodendroglioma |
sequence_alteration |
3.297% (3/91) |
1 entry |
ENSG00000100393 |
EP300 |
Pleural Epithelioid Mesothelioma |
sequence_alteration |
0.9756% (2/205) |
1 entry |
ENSG00000100393 |
EP300 |
Thymic Squamous Cell Carcinoma |
frameshift_variant |
7.407% (2/27) |
1 entry |
ENSG00000100393 |
EP300 |
solitary fibrous tumor |
missense_variant |
3.448% (1/29) |
1 entry |
ENSG00000100393 |
EP300 |
cervical carcinoma |
missense_variant |
8.696% (2/23) |
1 entry |
ENSG00000100393 |
EP300 |
small cell lung carcinoma |
conservative_inframe_deletion |
6.843% (31/453) |
1 entry |
ENSG00000100393 |
EP300 |
leiomyosarcoma |
missense_variant |
0.9901% (1/101) |
1 entry |
ENSG00000100393 |
EP300 |
acute lymphoblastic leukemia |
sequence_alteration |
0.9547% (4/419) |
1 entry |
ENSG00000100393 |
EP300 |
gastric adenocarcinoma |
stop_gained |
2.839% (27/951) |
1 entry |
ENSG00000100393 |
EP300 |
pancreatic ductal adenocarcinoma |
stop_gained |
1.966% (34/1729) |
1 entry |